| editorial | Q871232 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17460441.2013.768984 |
| P953 | full work available at URL | https://www.tandfonline.com/doi/pdf/10.1517/17460441.2013.768984 |
| P698 | PubMed publication ID | 23373702 |
| P50 | author | Lucas Moreno | Q89660375 |
| P2093 | author name string | Andrew D. J. Pearson | |
| P2860 | cites work | The Valley of Death in anticancer drug development: a reassessment | Q26861274 |
| European Journal of Cancer | Q27714869 | ||
| Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. | Q27851485 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| How to improve R&D productivity: the pharmaceutical industry's grand challenge | Q28314992 | ||
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| How were new medicines discovered? | Q29616641 | ||
| Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse | Q29620396 | ||
| PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer | Q33715936 | ||
| The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee | Q33732581 | ||
| Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. | Q34038793 | ||
| Adaptive design clinical trials: Methodology, challenges and prospect | Q34138180 | ||
| A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer | Q34192568 | ||
| Diagnosing the decline in pharmaceutical R&D efficiency | Q34257771 | ||
| Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer | Q35555293 | ||
| Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification | Q36437048 | ||
| Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns | Q36469916 | ||
| Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials | Q36622291 | ||
| Randomized phase II designs. | Q37173942 | ||
| Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies | Q37337123 | ||
| Some drop-the-loser designs for monitoring multiple doses | Q37775580 | ||
| Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?: TABLE 1 | Q37782511 | ||
| Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs | Q37798159 | ||
| Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice | Q37871253 | ||
| The productivity crisis in pharmaceutical R&D. | Q37883027 | ||
| Genetically engineered murine models – Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma | Q37940719 | ||
| Targeted agents: how to select the winners in preclinical and early clinical studies? | Q37957471 | ||
| Preclinical drug development for childhood cancer | Q38014543 | ||
| JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer | Q39226686 | ||
| A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer | Q39336570 | ||
| Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 | Q42031842 | ||
| Targeting IGF-1R: throwing out the baby with the bathwater? | Q42606238 | ||
| Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. | Q43522827 | ||
| Publication and Reporting Conduct for Pharmacodynamic Analyses of Tumor Tissue in Early-Phase Oncology Trials | Q43863913 | ||
| Applicability of a "Pick a Winner" trial design to acute myeloid leukemia | Q45416985 | ||
| Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop | Q50904356 | ||
| The inverted pyramid of biomarker-driven trials | Q51689988 | ||
| Envisioning the future of early anticancer drug development | Q51819134 | ||
| Compressing drug development timelines in oncology using phase '0' trials | Q53208031 | ||
| Loss of suppressor-of-fused function promotes tumorigenesis | Q53334228 | ||
| Anticancer drug development: the grand challenges. | Q55052796 | ||
| Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies | Q62664175 | ||
| Do molecularly targeted agents in oncology have reduced attrition rates? | Q82604498 | ||
| Medicines for pediatric oncology: can we overcome the failure to deliver? | Q85344832 | ||
| Improving Publication Rates of Biomarker Results from Cancer Trials | Q87422795 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug discovery | Q1418791 |
| P304 | page(s) | 363-368 | |
| P577 | publication date | 2013-02-04 | |
| P1433 | published in | Expert Opinion on Drug Discovery | Q5421204 |
| P1476 | title | How can attrition rates be reduced in cancer drug discovery? | |
| P478 | volume | 8 |
| Q39251464 | A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms. |
| Q90669751 | Assays for tyrosine phosphorylation in human cells |
| Q36772192 | Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells |
| Q92946963 | Cancer drug development: The missing links |
| Q35376170 | Characterization of a murine model of metastatic human non-small cell lung cancer and effect of CXCR4 inhibition on the growth of metastases |
| Q35891430 | Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme |
| Q101356068 | Cucurbitacin Mediated Regulation of Deregulated Oncogenic Signaling Cascades and Non-coding RNAs in Different Cancers: Spotlight on JAK/STAT, Wnt/β-catenin, mTOR, TRAIL-mediated pathways |
| Q28315265 | Development and characterization of a microfluidic model of the tumour microenvironment |
| Q93167028 | Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity |
| Q42346523 | Human tissue models in cancer research: looking beyond the mouse |
| Q50125592 | Inventing new therapies without reinventing the wheel: the power of drug repurposing |
| Q91525731 | Long-term monitoring in a microfluidic system to study tumour spheroid response to chronic and cycling hypoxia |
| Q28541848 | Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres |
| Q47621738 | New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels. |
| Q38096798 | Novel therapies for children with acute myeloid leukaemia. |
| Q52584649 | PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials. |
| Q92365620 | Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery |
| Q52576799 | Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer. |
| Q26824536 | Predictive biomarkers in precision medicine and drug development against lung cancer |
| Q35158519 | Real-time cytotoxicity assays in human whole blood |
| Q39708806 | Safety pharmacology investigations on the nervous system: An industry survey |
| Q41009718 | Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance |
| Q28067096 | Stimulated Raman scattering microscopy: an emerging tool for drug discovery |
| Q41336378 | Strain echocardiography combined with pharmacological stress test for early detection of anthracycline induced cardiomyopathy |
| Q26775582 | Synthetic biology for pharmaceutical drug discovery |
| Q38540135 | Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic |
| Q91744753 | The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models |
| Q35635673 | The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease |
| Q92969717 | The role of mouse tumour models in the discovery and development of anticancer drugs |
| Q41812382 | Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials |
| Q92259160 | ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer |
Search more.